MedTrace Logo

Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)

NCT02115724 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2025-01-28

No results posted yet for this study

Summary

Cardiovascular disease is the leading cause of death in the United States. Other studies have shown that stress, early in life, could be a risk factor for cardiovascular disease, later in life. This study will look at the effect of early life stressors on your cardiovascular health.

Conditions

Interventions

DIETARY_SUPPLEMENT

Antioxidant cocktail

Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment

OTHER

Biopsy

Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying

OTHER

Placebo

Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment

DRUG

NMD; 0.4mg sub-lingual nitroglycerin spray

Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Augusta University

    lead OTHER

Principal Investigators

  • Ryan Harris, PhD · Augusta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2026-12-31
Completion
2027-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02115724 on ClinicalTrials.gov